Severin J. Jacobi

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

C. Klein, S. Endres, S. Kobold, 2018, British Journal of Cancer.

A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice

R. Baumgartner, S. Endres, S. Strobl, 2016, Oncoimmunology.

Hypothermic Oxygenated Machine Perfusion (HOPE) Prior to Liver Transplantation Mitigates Post-Reperfusion Syndrome and Perioperative Electrolyte Shifts

M. Guba, J. Werner, Severin J. Jacobi, 2022, Journal of clinical medicine.

Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma

F. Klauschen, D. Anz, T. G. Grünewald, 2022, bioRxiv.

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

C. Klein, S. Endres, S. Kobold, 2018, British Journal of Cancer.